RxDoctor Payments DataLook up a doctor →

Flint Packer, DO

Family Medicine · Idaho Falls, IDNPI 1932259892

Payments from drug & device makers

$587,469in general payments, 2019–2025

Across 648 payments — averaging $906.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$578K
  • AbbVie$2K
  • Lilly USA, LLC$787
  • Boehringer Ingelheim$636
  • Novo Nordisk$631
  • Amgen$623
  • plus $5K from 54 others
$1,000in research payments, 2019–2025

Across 2 payments — averaging $500.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1K

What the payments were for

  • Food & beverage$9,625100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly13$577,830
AbbVie(2 entities)132$2,282
Lilly USA, LLC67$787
Boehringer Ingelheim37$636
Novo Nordisk56$631
Amgen(2 entities)49$623
Astellas Pharma US Inc22$411
Otsuka America Pharmaceutical, Inc.22$333
Antares Pharma, Inc.16$276
GSK19$275
Teva Pharmaceuticals USA, Inc.15$211
Axsome Therapeutics, Inc.15$196
AstraZeneca13$168
Novartis9$160
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$142
Bayer9$134
CSL Behring5$124
Vanda Pharmaceuticals Inc.4$116
Phathom Pharmaceuticals, Inc.10$93
Takeda Pharmaceuticals U.S.A., Inc.7$93
Pfizer6$87
Lundbeck LLC4$87
Genentech USA, Inc.6$87
Dexcom, Inc.4$87
Sanofi Pasteur Inc.4$79
Esperion Therapeutics, Inc.5$68
Biocryst US Sales Co., LLC3$67
Merck4$67
Aimmune Therapeutics, Inc.4$66
Sunovion Pharmaceuticals Inc.5$64
Amarin Pharma, Inc.4$61
Ironshore Pharmaceuticals Inc.3$57
Shield Therapeutics Inc3$56
Corcept Therapeutics3$54
Nestle Healthcare Nutrition Inc.3$53
Corium, LLC6$53
Boston Scientific3$53
Ionis Pharmaceuticals, Inc.2$49
Relievant Medsystems, Inc.1$44
Mylan Specialty L.p.2$40
Pharming Healthcare, Inc.3$39
Alnylam Pharmaceuticals Inc.2$37
Supernus Pharmaceuticals, Inc.2$37
Neurocrine Biosciences, Inc.2$37
Johnson & Johnson2$33
Shire North American Group Inc2$30
Biocryst Pharmaceuticals, Inc.1$30
Eisai Inc.2$29
Gilead2$29
Impel Pharmaceuticals Inc.2$28
Averitas Pharma Inc.1$27
Adlon Therapeutics L.p.2$26
Abbott1$23
Sanofi-aventis U.S. LLC2$22
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$20
Seqirus USA Inc1$18
Acadia Pharmaceuticals Inc1$18
Neurelis, Inc.1$18
Upsher-smith Laboratories LLC1$17
Si-bone, Inc.1$17

How this compares

$587,469 in reported general payments places this provider in the 95th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$179,389
Medicare patients
386
Services billed
3,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HaegardaC1 Esterase Inhibitor24$664,303
MounjaroTirzepatide134$177,563
JardianceEmpagliflozin124$113,964
OzempicSemaglutide60$82,746
TrulicityDulaglutide59$70,292
EliquisApixaban74$69,977
FarxigaDapagliflozin Propanediol59$41,859
XareltoRivaroxaban19$21,169
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,691
ShingrixVaricella-Zoster Ge/As01b/Pf53$11,633
LinzessLinaclotide13$8,690
Desvenlafaxine Succinate ErDesvenlafaxine Succinate69$8,526
MotegrityPrucalopride Succinate14$8,475
Solifenacin Succinate13$6,769
Tresiba Flextouch U-100Insulin Degludec24$5,921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHaegarda$124$664,30324 claims
Lilly USA, LLCMounjaro, Trulicity$787$247,855193 claims
Boehringer IngelheimJardiance$636$113,964124 claims
Novo NordiskOzempic$631$82,74660 claims
PfizerEliquis$87$69,97774 claims
AstraZenecaFarxiga$168$41,85959 claims
GSKTrelegy Ellipta, Shingrix$275$28,32471 claims
Johnson & JohnsonXarelto, Risperdal$33$24,11332 claims
AbbVieLinzess, Synthroid$2,282$10,71365 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$93$8,47514 claims
Sanofi-aventis U.S. LLCLantus$22$1,84512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 803 family medicine providers in Idaho.

Other family medicine in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →